Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 297

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis

Open access
Janssen, Quisette P, Buettner, Stefan, Suker, Mustafa, Beumer, Berend R, Addeo, Pietro, Bachellier, Philippe, Bahary, Nathan, Bekaii-Saab, Tanios, Bali, Maria A, Besselink, Marc G, Boone, Brian A, Chau, Ian, Clarke, Stephen, Dillhoff, Mary, El-Rayes, Bassel F, Frakes, Jessica M, Grose, Derek, Hosein, Peter J, Jamieson, Nigel B, Javed, Ammar A, Khan, Khurum, Kim, Kyu-Pyo, Kim, Song Cheol, Kim, Sunhee S, Ko, Andrew H, Lacy, Jill, Margonis, Georgios A, McCarter, Martin D, McKay, Colin J, Mellon, Eric A, Moorcraft, Sing Yu, Okada, Ken-Ichi, Paniccia, Alessandro, Parikh, Parag J, Peters, Niek A, Rabl, Hans, Samra, Jaswinder, Tinchon, Christoph, van Tienhoven, Geertjan, van Veldhuisen, Eran, Wang-Gillam, Andrea, Weiss, Matthew J, Wilmink, Johanna W, Yamaue, Hiroki, Homs, Marjolein Y V, van Eijck, Casper H J, Katz, Matthew H G, Groot Koerkamp, Bas·2019·JNCI: Journal of the National Cancer Institute

Abstract

Background: FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients. The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer (BRPC) remains debated. Methods: We performed a systematic review and patient-level meta-analysis on neoadjuvant FOLFIRINOX in patients with BRPC. Studies with BRPC patients who received FOLFIRINOX as first-line neoadjuvant treatment were included. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival, resection rate, R0 resection rate, and grade III–IV adverse events. Patient-level survival outcomes were obtained from authors of the included studies and analyzed using the Kaplan-Meier method. Results: We included 24 studies (8 prospective, 16 retrospective), comprising 313 (38.1%) BRPC patients treated with FOLFIRINOX. Most studies (n = 20) presented intention-to-treat results. The median number of administered neoadjuvant FOLFIRINOX cycles ranged from 4 to 9. The resection rate was 67.8% (95% confidence interval [CI] = 60.1% to 74.6%), and the R0-resection rate was 83.9% (95% CI = 76.8% to 89.1%). The median OS varied from 11.0 to 34.2 months across studies. Patient-level survival data were obtained for 20 studies representing 283 BRPC patients. The patient-level median OS was 22.2 months (95% CI = 18.8 to 25.6 months), and patient-level median progression-free survival was 18.0 months (95% CI = 14.5 to 21.5 months). Pooled event rates for grade III–IV adverse events were highest for neutropenia (17.5 per 100 patients, 95% CI = 10.3% to 28.3%), diarrhea (11.1 per 100 patients, 95% CI = 8.6 to 14.3), and fatigue (10.8 per 100 patients, 95% CI = 8.1 to 14.2). No deaths were attributed to FOLFIRINOX. Conclusions: This patient-level meta-analysis of BRPC patients treated with neoadjuvant FOLFIRINOX showed a favorable median OS, resection rate, and R0-resection rate. These results need to be assessed in a randomized trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djz073

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 297

Metadata

Authors
Janssen, Q. P., Buettner, S., Suker, M., Beumer, B. R., Addeo, P., Bachellier, P., Bahary, N., Bekaii-Saab, T., Bali, M. A., Besselink, M. G., Boone, B. A., Chau, I., Clarke, S., Dillhoff, M., El-Rayes, B. F., Frakes, J. M., Grose, D., Hosein, P. J., Jamieson, N. B., Javed, A. A., Khan, K., Kim, K.-P., Kim, S. C., Kim, S. S., Ko, A. H., Lacy, J., Margonis, G. A., McCarter, M. D., McKay, C. J., Mellon, E. A., Moorcraft, S. Y., Okada, K.-I., Paniccia, A., Parikh, P. J., Peters, N. A., Rabl, H., Samra, J., Tinchon, C., van Tienhoven, G., van Veldhuisen, E., Wang-Gillam, A., Weiss, M. J., Wilmink, J. W., Yamaue, H., Homs, M. Y. V., van Eijck, C. H. J., Katz, M. H. G., & Groot Koerkamp, B.
Venue
JNCI: Journal of the National Cancer Institute
Published
2019-05-14
Volume
111
Issue
8
Pages
782-794
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2946040614
Cited by
297
References
47
FWCI
4.98
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. https://app.cochat.ai/papers/10.1093/jnci/djz073
The paper
Janssen, Q. P., Buettner, S., Suker, M., Beumer, B. R., Addeo, P., Bachellier, P., Bahary, N., Bekaii-Saab, T., Bali, M. A., Besselink, M. G., Boone, B. A., Chau, I., Clarke, S., Dillhoff, M., El-Rayes, B. F., Frakes, J. M., Grose, D., Hosein, P. J., Jamieson, N. B., . . . Groot Koerkamp, B. (2019). Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djz073

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.